This Week's Poll

At the recent BioPartner Forum it was stated the internal market is insufficient for a UK Life Science company to develop a technology, product or service at a rate that will return investor value. Do you

Supported by Medilink UK

IVDs investment - Ashley Yeo of - ClinicaScrip - 14:32:41pm Aug-11th

(Principal Analyst - Healthcare Editor at Clinica-Scrip) The IVDs sector in the UK needs a long-term commitment to the early health model. A simply structured, well worded commitment to promoting, using and monitoring use of these technologies will result in benefits all round - to patients, to the healthcare system, and thus to the government. Too little is invested in this vital segment from the UK healthcare budget.
Click here for more

Agree/Disagree + add comment
Thumbs Up1 person agrees with this
 
 
t